Efficacy and safety of intravitreal faricimab in Japanese patients with diabetic macular edema

Efficacy and safety of intravitreal faricimab in Japanese patients with diabetic macular edema - Intravitreal injection of faricimab on diabetic maculopathy

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000049916

Enrollment

Registered

2023-01-01

Start date

2023-01-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic maculopathy

Interventions

Intravitreal injection of faricimab

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with diabetic macular edema who are outpatients in the department of Ophthalmology, Seirei Hamamatsu General Hospital and judged to be suitable for faricimab treatment. Patients signed in written informed consent form

Exclusion criteria

Exclusion criteria: Patients who have received the other treatment for diabetic macular edema

Design outcomes

Primary

Measure	Time frame
best corrected visual acuity	—

Secondary

Measure	Time frame
central macular thickness	—

Countries

Japan

Contacts

Public ContactAkira Obana

Seirei Hamamatsu General Hospital Department of Ophthalmology

obana@sis.seirei.or.jp0534742222

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026